|Mr. Mark A. Emalfarb||Founder, Chief Exec. Officer, Pres and Director||654.2k||N/A||61|
|Mr. Thomas L. Dubinski CPA||Chief Financial Officer, VP and Corp. Sec.||306.67k||N/A||60|
|Mr. Matthew S. Jones||Managing Director of Bus. Devel. & Licensing||173.24k||N/A||N/A|
|Dr. Ronen Tchelet Ph.D.||VP of Research & Bus. Devel..||181.09k||N/A||59|
Dyadic International, Inc., a biotechnology company, discovers, engages in the discovery, development, manufacture, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and manufacture of enzymes and other proteins for various markets. The company offers liquid and dry enzyme products; develops tools for gene expression via its proprietary fungal host, Myceliopthora Thermophila or C1; and provides research and development services for third parties, licenses its technologies. It serves the bioenergy, biochemical, industrial enzyme, biopharmaceutical, animal health and nutrition, pulp and paper, food, and textiles industries. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Dyadic International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.